Pralatrexate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 20 mg/mL
Reference Brands: Folotyn (USA)
Category:
Oncology Cancer Care
Pralatrexate is available in Injection
and strengths such as 20 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pralatrexate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pralatrexate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pralatrexate is an antineoplastic agent marketed under the brand name Folotyn and is used in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It belongs to the class of folate analog metabolic inhibitors and is specifically designed to target rapidly dividing malignant cells. Pralatrexate selectively enters cancer cells through the reduced folate carrier, which is often overexpressed in lymphoma cells, allowing enhanced intracellular accumulation of the drug.
Once inside the cell, pralatrexate inhibits dihydrofolate reductase, an essential enzyme involved in folate metabolism and DNA synthesis. This inhibition disrupts the production of nucleotides required for cell replication, ultimately leading to cell cycle arrest and apoptosis of cancer cells. Due to its targeted mechanism, pralatrexate offers a therapeutic option for patients whose disease has progressed despite prior systemic treatments.
Pralatrexate is administered intravenously and is typically used under specialist oncology supervision. To reduce treatment-related toxicity, supplementation with folic acid and vitamin B12 is recommended before and during therapy. Folotyn represents an important treatment option for patients with limited alternatives in the management of aggressive and difficult-to-treat peripheral T-cell lymphoma.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing